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Background: Defects in programmed cell death, or apoptosis, are a hallmark of cancer. The anti-apoptotic B-cell
lymphoma 2 (BCL-2) family proteins, including BCL-2, BCL-XL, and MCL-1 have been characterized as key survival
factors in multiple cancer types. Because cancer types with BCL2 and MCL1 amplification are more prone to
inhibition of their respectively encoded proteins, we hypothesized that cancers with a significant frequency of
BCL2L1 amplification would have greater dependency on BCL-XL for survival.
Methods: To identify tumor subtypes that have significant frequency of BCL2L1 amplification, we performed data
mining using The Cancer Genome Atlas (TCGA) database. We then assessed the dependency on BCL-XL in a panel
of cell lines using a selective and potent BCL-XL inhibitor, A-1155463, and BCL2L1 siRNA. Mechanistic studies on the
role of BCL-XL were further undertaken via a variety of genetic manipulations.
Results: We identified colorectal cancer as having the highest frequency of BCL2L1 amplification across all tumor
types examined. Colorectal cancer cell lines with BCL2L1 copy number >3 were more sensitive to A-1155463.
Consistently, cell lines with high expression of BCL-XL and NOXA, a pro-apoptotic protein that antagonizes MCL-1
activity were sensitive to A-1155463. Silencing the expression of BCL-XL via siRNA killed the cell lines that were
sensitive to A-1155463 while having little effect on lines that were resistant. Furthermore, silencing the expression
of MCL-1 in resistant cell lines conferred sensitivity to A-1155463, whereas silencing NOXA abrogated sensitivity.
Conclusions: This work demonstrates the utility of characterizing frequent genomic alterations to identify
cancer survival genes. In addition, these studies demonstrate the utility of the highly potent and selective
compound A-1155463 for investigating the role of BCL-XL in mediating the survival of specific tumor types, and
indicate that BCL-XL inhibition could be an effective treatment for colorectal tumors with high BCL-XL and NOXA
expression.
Keywords: BCL-XL, MCL-1, NOXA, BCL-XL inhibitor, Colorectal cancerBackground
Cancer is a genetic disease that arises from the accumu-
lation of somatic gene alterations. One way to identify
key genes in cancer is to examine genomic regions that
undergo frequent alterations. Recent technological ad-
vances in characterizing these alterations make it* Correspondence: Lloyd.Lam@abbvie.com
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creativecommons.org/publicdomain/zero/1.0/possible to identify genes that are essential for the initi-
ation and/or survival of cancer, and thus encode poten-
tial therapeutic targets.
Evasion of apoptosis is a hallmark of cancer cells. One
mechanism of apoptotic pathway deregulation is via up-
regulation of the anti-apoptotic BCL-2 family members.
Apoptotic pathway proteins belong to a family of BCL-2
Homology (BH)-domain-containing proteins comprising
three classes: 1) multi-domain anti-apoptotic (BCL-2,
BCL-XL, BCL-W, BFL-1/A1, and MCL-1), 2) multi-
domain pro-apoptotic (BAX, BAK), and 3) BH3-onlyticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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BMF, and HRK). The BH3-only proteins contain a single
BH3 domain and are bound by specific anti-apoptotic pro-
teins [1]. For example, BCL-2 and BCL-XL bind and
antagonize BIM but not NOXA. In contrast, MCL-1 and
A1 bind and antagonize NOXA but not BAD protein.
Other BH3 domain proteins such as BIM and PUMA are
bound and antagonized by all anti-apoptotic proteins.
BAX and BAK are known as the “effectors”. Once acti-
vated, these proteins oligomerize on the outer mito-
chondrial membrane and induce pore formation; this
results in the release of cytochrome c and other pro-
apoptotic proteins that ultimately carry out the cell
death mechanism.
The role of anti-apoptotic BCL-2 family proteins in
various cancers has been well studied [2]. BCL-2 was ini-
tially identified from the breakpoint of the t(14;18)
chromosomal translocation found in over 60 % of indo-
lent B cell non-Hodgkin’s lymphoma [3–6]. In addition
to the vast majority of follicular lymphomas, many ger-
minal center B cell (GCB) subtype diffuse large B cell
lymphomas (DLBCL) also exhibit the t(14;18) chromo-
somal translocation [7–9]. BCL2 amplification is also de-
tected in many hematologic malignancies such as the
activated B cell-like (ABC) subtype of DLBCL [10]. Not
surprisingly, cell lines with the translocation or amplifi-
cation are more sensitive to the selective BCL-2 inhibitor
ABT-199 [11].
MCL1 was reported to be amplified in 10.9 % of tumor
samples analyzed, spanning multiple cancer subtypes
[12]. Fluorescence in situ hybridization (FISH) of the
MCL1 region identified lung and breast cancers as hav-
ing significantly higher frequencies of focal amplification,
suggesting that these tumors depend on MCL-1 for sur-
vival. This is supported by multiple studies demonstrat-
ing that cell lines with MCL1 amplification are sensitive
to siRNA knockdown of MCL1 [12, 13].
BCL-XL has been implicated as a key survival factor in
numerous solid tumors [2]. Based on the evidence that
cancer types with BCL2 and MCL1 amplification are more
prone to inhibition of their encoded proteins, we hypothe-
sized that cancers with a significant frequency of BCL2L1
amplification are more dependent on BCL-XL for survival.
In this study, we identified colorectal cancer as having a
significant incidence of BCL2L1 amplification. We then
dissected the role of BCL-XL in colorectal cancer cell lines
using a selective small-molecule inhibitor of BCL-XL and
a variety of genetic manipulations.
Materials and methods
Reagents
BCL-XL inhibitor A-1155463 and navitoclax were synthe-
sized at AbbVie, Inc. (North Chicago, IL). All the siRNAs
were purchased from Dharmacon (Lafayette, CO).Cell culture, transfection, and cell-based assays
Colorectal cell lines (ATCC) were cultured in RPMI
(Invitrogen, Carlsbad, CA) supplemented with 10 % fetal
bovine serum (FBS) (Invitrogen), 1 % sodium pyruvate
(Invitrogen), and 4.5 g/L glucose (Sigma, MO), or
DMEM (Invitrogen) supplemented with 10 % FBS. All
the lines were maintained in a humidified chamber at
37 °C containing 5 % CO2.
LS1034, SW1417, GEO, and RKO cells were trans-
fected in 6-well plates with siRNAs using Lipofectamine
2000 according to the manufacturer’s instructions
(Invitrogen). A final concentration of 20 nM siRNA
was used in all cases. The sense sequences of the BCL-
XL siRNA used is ACAAGGAGAUGCAGGUAUUUU
(Dharmacon). The sense sequences of the MCL-1 siRNAs
used is GCATCGAACCATTAGCAGATT (Dharmacon).
The cells were then grown in medium without antibiotic
before harvesting for western blotting analysis. LS1034
cells were transfected at 1.5–2.5 × 104 cells/100 μl in
96-well tissue culture plates with 20 nM Noxa siRNA
pool (Dharmacon). The cells were grown in medium
without antibiotic before harvesting.
Cells were treated with increasing concentration of A-
1155463. Cells were assayed for viability after 72 h using
the CellTiter-Glo luminescent cell viability assay accord-
ing to the manufacturer’s protocol (Promega, Madison,
WI). Results were normalized to cells without treatment.
EC50 was calculated using the GraphPad Prism software
(La Jolla, CA).Western blot analysis
Cell lysates were prepared in RIPA buffer (Sigma) plus
protease inhibitor cocktail (Roche). 20 μg of total pro-
tein was resolved on a 12 % SDS polyacrylamide gel
and probed with anti-BCL-XL (Epitomics, Burlingame,
CA), anti-MCL-1 (Epitomics), anti-BCL-2 (BD), anti-
BIM (Epitomics), anti-actin and anti-NOXA (Abcam,
Cambridge, MA). Antibody against tubulin (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was used as a
loading control.Fluorescence-activated cell sorting (FACS) analysis
LS1034 cells were treated with DMSO or 200 nM A-
1155463, with or without 50 μM Z-VAD caspase in-
hibitor (Santa Cruz Biotechnology, Inc.) for 72 h. DNA
content was measured by flow cytometry to determine
the effect of the inhibitors on the cell cycle and cell
death. Following treatment, cells were spun down, the
medium was removed and the cells were resuspended
in staining solution (50 μg propidium iodide, 40 U/ml
RNase, 0.1 % triton X-100 in PBS) at a cell concentration
of 1 × 106 cells/ml. The cells were stored in the dark at
room temperature for at least 30 min or up to 24 h at 4 °C
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try using a FACS Calibur (BD Biosciences, San Jose, CA).
Results
BCL-XL has been implicated as a key survival factor in
numerous solid tumors. Since cancer types with BCL2
and MCL1 amplification are more prone to inhibition of
these proteins, we reasoned that significant frequency of
BCL2L1 amplification in a particular cancer type may in-
dicate dependency on BCL-XL for survival. To identify
cancer types with a significant amplification of BCL2L1,
we utilized The cBio Cancer Genomics Portal (http://
cbioportal.org), an open-access resource for interactive
exploration of multidimensional cancer genomics data
sets from more than 5,000 tumor samples from 20 cancer
studies [14]. We surveyed the percentage of copy number
alternations of BCL2, BCL2L1 and MCL1 among a major-
ity of these tumor samples (Fig. 1a) and found that colo-
rectal cancer has the highest percentage of BCL2L1 gain/
amplification among all cancer types. Out of 212 samples,
15 % have BCL2L1 amplification, while MCL1 amplifica-
tion is found in only 1 %. BCL2 amplifications were not
observed, although homozygous deletion is observed in
1 % of colorectal cancer samples (data not shown). Fur-
thermore, there is a good correlation between BCL2L1
copy number gain/amplification and gene expression as
determined by RNAseq and microarray analysis (Fig. 1b
and data not shown). Cervical cancer also has a high per-
centage of BCL2L1 gains/amplifications (Fig. 1a) although
the sample numbers are limited. Consistent with other
studies, we found that DLBCL has the highest percentageA B
% of sample with amplification
Tumor type (no. of samples) BCL2 BCL2L1 MCL1 Total
DLBCL (18) 11 6 0 17
Colorectal (212) 0 15 1 16
Cervix (36) 0 14 6 20
Lung adeno (129) 3 5 20 28
Liver (139) 0 1 17 18
Bladder (127) 0 7 16 23
Breast (760) 3 2 15 20
Ovary (311) 3 7 13 23
Uterine (240) 1 5 9 15
Sarcoma (83) 5 4 8 17
Melanoma (228) 0 1 4 5
Head and neck (279) 0 5 3 8
Glioma (218) 1 0 1 2
AML (187) 0 1 0 1
Pancreas (42) 0 0 0 0
CCLE (881) 8 8 10 26
Fig. 1 Cross-cancer tumor sample analysis identified colorectal cancer as h
alteration summary for BCL2, BCL2L1 and MCL1 based on data obtained fro
expression and copy number alteration of BCL2L1 in 212 colorectal cancerof BCL2 amplification (11 %) and lung adenocarcinoma
has the highest percentage of MCL1 amplification
(20 %) (Fig. 1a). These data indicated that each tumor
type has a selective dependency on a particular anti-
apoptotic protein for survival and colorectal and cer-
vical tumors are potentially more dependent on BCL-XL
for survival.
To test this hypothesis, we selected a panel of 25 colo-
rectal cancer cell lines with known copy number of
BCL2L1. We first investigated the sensitivity of these
colorectal cell lines to treatment with the selective BCL-
XL inhibitor, A-1155463 ([15] and Fig. 2a). This recently
reported small molecule is more potent in inhibiting
BCL-XL than navitoclax but shows negligible activity
against BCL-2 or MCL-1, thus making it an excellent
tool for dissecting BCL-XL cancer biology. A-1155463
demonstrated strong growth inhibition of over half of
the colorectal cell lines (Fig. 2b) as defined by EC50
values ≤0.5 μM in the presence of 10 % FBS. Consistent
with its lower potency against BCL-XL, navitoclax in-
duced cell death in the same cell lines, although at
higher concentrations (data not shown).
Previously, we and others have shown that copy num-
ber (CN) gain, protein and mRNA expression of BCL-2
family members is a crucial determinant of sensitivity to
BH3 mimetics such as ABT-737, an inhibitor of BCL-2,
BCL-XL, and BCL-W, and ABT-199, a specific inhibitor
of BCL-2 [11, 16–18]. Herein we report for the first time
that cell lines with BCL2L1 gains are sensitive to selective
BCL-XL inhibition. Among the 11 lines with BCL2L1 gain
(CN > 3), 9 are sensitive to A-1155463 (EC50 < 0.5 μM). Inaving the highest frequency of BCL2L1 amplification. a Cross-cancer
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Fig. 2 Colon cancer cell lines with BCL2L1 gain are more sensitive to BCL-XL inhibitor. a Structure of the potent and specific BCL-XL inhibitor
A-1155463. b Colorectal cell lines were treated with increasing concentrations of A-1155463. Cells were assayed for viability after 72 h. Results
were normalized to cells without treatment. Each cell line was treated with A-1155463 in at least 3 different experiments and the average EC50 is
presented. BCL2L1 copy number gain >3 is indicated with + or -. Mutation status of APC and β-catenin is also indicated with + or -. These data are
taken from the CCLE database [24]. N denotes cases where data were not available
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BCL2L1 are sensitive to A-1155463 (Fig. 2b).
To determine if expression of BCL-2 family members
plays a role in the sensitivity of colorectal cell lines to A-
1155463, we collected lysates from these cell lines and
performed western blotting analysis. Colorectal cell lines
within our panel expressed varying levels of MCL-1 and
BCL-XL (Fig. 3a). In general, there was an inverse rela-
tionship between the expression of MCL-1 versus
NOXA and BCL-XL. We observed a strong correlation
(0.68) between cell lines with BCL2L1 gain and BCL-XL
protein expression. In addition, sensitive lines had higher
protein expression of BCL-XL (p = 0.0002) and NOXA
(p = 0.02), higher BCL-XL to MCL-1 ratio (p = 0.0027),
and a trend towards lower expression of MCL-1, al-
though not statistical significant (p = 0.12). The Pearson
correlation between log EC50 and expression of BCL-XL,
NOXA, MCL-1, and BCL-XL/MCL-1 was 0.75, 0.653,
0.363, and 0.637, respectively. The Spearman correlation
between EC50 and expression of BCL-XL, NOXA, MCL-
1, and BCL-XL/MCL-1 was 0.789, 0.749, 0.277, and
0.795, respectively. BCL-2 expression was detected in a
single line, consistent with other studies showing thatBCL-2 expression is less common in solid tumor cell
lines [19]. To confirm these findings, we performed cor-
relation analyses with mRNA expression data. There was
a strong correlation between protein and mRNA expres-
sion for MCL-1 and BCL-XL. Additionally, sensitive lines
had higher expression of BCL2L1 (p = 0.0078) and
NOXA (p = 0.02), a higher BCL2L1 to MCL1 ratio (p =
0.0086), and a trend towards lower expression of MCL1
mRNA, although not statistical significant (p = 0.15)
(Fig. 3b). The correlation coefficients for BCL2L1 and
MCL1 versus sensitivity were −0.41 and 0.56, respect-
ively, while the correlation coefficient for the BCL2L1 to
MCL1 ratio was −0.56. These data indicate that BCL2L1
and NOXA expression may play important roles in de-
termining sensitivity to selective BCL-XL inhibitors.
Two recent manuscripts reported that BCL-XL is regu-
lated by the β-catenin pathway. In an unbiased screen of
242 genomically characterized cancer cell lines with an
Informer Set of 354 small molecules, cell lines with β-
catenin mutation were reported to be amongst the most
sensitive to navitoclax (ABT-263), an inhibitor of BCL-2,
BCL-XL and BCL-W [20]. In a separate study, β-catenin-

















































































































Fig. 3 Colon cancer cell lines with high BCL-XL and NOXA are more sensitive to BCL-XL inhibitor. a Protein expression of BCL-2 family members
in colorectal cancer cell lines. BCL2L1 copy number gains >3 is indicated with + or -. b Protein and mRNA expression of BCL-XL, NOXA, MCL-1,
and ratio of BCL-XL /MCL-1 in A-1155463-sensitive vs. resistant colorectal cancer cell lines
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YAP1 and the transcription factor TBX5, both of which
form a complex with β-catenin [21]. This complex was
further shown to be important for regulating BCL-XL
and the anti-apoptotic gene BIRC5. APC is part of a de-
struction complex that mediates the ubiquitin-targeted
proteolysis of β-catenin. Mutations in APC destabilize
this complex and lead to the accumulation of β-catenin,
which can then translocate to the nucleus and aberrantly
activate the transcription of key drivers of oncogenesis
[22]. Interestingly, a small subgroup of colorectal tumors
with wild-type APC has point mutations in β-catenin
that allow it to escape degradation [23]. Since BCL-XL
was described to be regulated by the β-catenin pathway
and multiple components of the pathway are highly mu-
tated in colorectal cancer, we determined whether a cor-
relation exists between these mutations and the activityof inhibitor A-1155463 in the colorectal cancer cell lines.
While the majority of these lines have mutations in
APC, only two lines have β-catenin mutations according
to the Cancer Cell Line Encyclopedia (CCLE) [24]. Con-
trary to recent reports, we found no correlation between
APC or β-catenin mutation status and dependence on
BCL-XL for survival as revealed by sensitivity to A-
1155463 (Fig. 2b) or navitoclax (data not shown). This
could be explained by differences in cell lines between
the studies. In particular, our studies focus on colon cell
lines only. It is also possible that the disparity results
from the lack of appropriately selective small molecules
in the study by Basu et al. [20].
To confirm the survival dependence on BCL-XL within
the colorectal cell line panel, we silenced its expression
via small interfering RNA (siRNA) oligonucleotides spe-
cific to BCL2L1 in two sensitive (LS1034 and SW1417)
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two sensitive lines also exhibit BCL2L1 gain. BCL2L1
siRNA effectively knocked down BCL-XL protein expres-
sion completely in three cell lines, and ~80 % in SW1417
cells (Fig. 4a). However, the viability of only the A-1155463-
sensitive colorectal cell lines was greatly reduced after
transfecting BCL2L1 siRNA (defined as >50 % reduction).
In contrast, there was minimal effect on the viability of the
inhibitor-resistant cell lines, thus confirming that BCL-XL is
critical for survival of a subgroup of colorectal cell lines.
The viability is also confirmed using another assay that
quantifies the ATP present in culture as an indicator of
metabolically active cells (Fig. 4b). We found that the viabil-
ity measured with this method is similar to that as shown
in Fig. 4a, confirming that these A-1155463-sensitive colo-
rectal cell lines indeed depend on BCL-XL for survival.
To assess whether the BCL-XL inhibitor induced cell
death in sensitive colorectal cell lines via apoptosis, weA
B
Fig. 4 A-1155463 sensitivity correlates with the effect of BCL-XL knockdown
A-1155463-sensitive cell lines (LS1034 and SW1417) and two resistant cell line
Western blotting showing the degree of BCL-XL knock-down by BCL2L1 siRNA
shown as BCL-XL/actin. b Viability was determined after 72 h with CellTiter Gl
caspase-3/7 pathway. LS1034 and SW1417 cells were treated with DMSO or 2
24 h. DNA content was measured by flow cytometry to determine the effect
in each phase of the cell cycle was plottedevaluated the cell cycle distribution of LS1034 and
SW1417 cells after treatment with A-1155463 in the
presence or absence of the caspase-3/7 inhibitor Z-VAD.
As shown in Fig. 4c, A-1155463 treatment led to sub-
stantial accumulation of sub-G0/apoptosis cells (>50 %).
This effect was completely abrogated in the presence of
Z-VAD, indicating that cell killing occurs via the activa-
tion of caspase-3/7 pathway.
We investigated the role of MCL-1 in determining sensi-
tivity to the BCL-XL inhibitor in two resistant colorectal cell
lines (RKO and GEO) by silencing the expression of MCL-
1 with siRNA. While silencing MCL-1 alone had no effect
(data not shown), MCL-1 knockdown in the presence of A-
1155463 afforded complete cell killing (Fig. 5a). Similar ef-
fects were observed with an additional resistant line, HT-29
(data not shown). These data indicate that MCL-1 plays a
role in modulating sensitivity to BCL-XL inhibitors in colo-
rectal cancer cell lines.C
and apoptosis. BCL2L1 or control siRNA was transfected into two
s (GEO and RKO). a Viability was determined after 72 h by microscopy.
s. Levels of BCL-XL knockdown were measured by densitometry and
o reagent. c BCL-XL inhibitor induces apoptosis through activation of
00 nM A-1155463, with or without 50 μM Z-VAD caspase inhibitor for























Fig. 5 Silencing MCL1 sensitizes colorectal cells to BCL-XL inhibitor while silencing NOXA renders resistance to BCL-XL inhibitor. a MCL1 or control
siRNA were transfected into RKO and GEO cells in the presence of A-1155463. Viability was determined after 48 h by microscopy. Western blotting
showing the degree of MCL-1 knockdown by MCL1 siRNAs in GEO and RKO cells. b NOXA or control siRNA was transfected into LS1034 cells in
the presence or absence of A-1155463. Viability was determined after 48 h. Results were normalized to cells transfected with scrambled siRNA
control and presented as mean +/− SD (n = 3). *p < 0.01, **p < 0.005. Western blotting showing the degree of NOXA knockdown by NOXA
siRNA pool
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MCL-1 activity. Because NOXA expression is higher in
the sensitive lines (Fig. 3a), we sought to assess its role
in determining sensitivity to BCL-XL inhibitors. We thus
asked whether silencing NOXA would rescue sensitive
colorectal lines from treatment with A-1155463. Trans-
fection of LS1034 cells with NOXA siRNA rendered the
cells insensitive to A-1155463 treatment (Fig. 5b), indi-
cating that NOXA function, likely involving its inhib-
ition of MCL-1, is required to sensitize this cell line to
BCL-XL inhibition. Similar results were observed in an-
other BCL-XL inhibitor-sensitive line, SW1417 (data not
shown).
Discussion
In this study, we set out to first identify cancer types that
show high levels of BCL2L1 amplification using genomic
mining. Our second major aim was to investigate the de-
pendency of corresponding cell lines on BCL-XL for sur-
vival. To this end, we used not only siRNA but a
recently disclosed small molecule inhibitor of BCL-XL
that shows high potency and selectivity against otherpro-survival proteins. Our study identified colorectal
and cervical cancers as having the most frequent
BCL2L1 amplification. Further studies showed that the
majority of colorectal cancer cell lines with a gain in
BCL2L1 are sensitive to the selective BCL-XL inhibitor
A-1155463 as well as to siRNA-medited knockdown of
BCL2L1. Although the gains are typically modest (3–4.4
copies), it should be noted that CN gain of other anti-
apoptotic genes such as MCL1 is also modest in other
tumors that nevertheless become dependent on these
genes for survival [12]. In addition, the sensitive lines ex-
hibit higher protein and mRNA expression of BCL-XL
and NOXA, and a trend towards lower protein and
mRNA expression of MCL-1 than the resistant lines.
Despite a recent report that navitoclax-sensitive cell
lines are enriched with β-catenin mutations [20], we
found no correlation between BCL-XL dependence and
the presence of β-catenin or APC mutations. Possible
reasons for this discrepancy could be differences in the
colorectal cell lines used in the two studies, or alterna-
tively, the fact that the highly selective BCL-XL inhibitor
was not available at the time of the earlier study by Basu
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selectivity of the compound used [20]. Our data is con-
sistent with those of Rosenbluh et al., who reported that
β-catenin-active cancers regulate BCL-XL as a survival
factor [21]. In this regard, we found that sensitive lines
are enriched with an active β-catenin pathway as deter-
mined by a β-catenin transcriptional reporter assay. Al-
though this is a small sample size, preliminary data show
that five out of six of the sensitive lines display active β-
catenin pathway versus three out of six in the resistant
group (data not shown). Collectively, our data indicate
that BCL-XL may be regulated through multiple path-
ways in colorectal cancer, including CN gain and active
β-catenin signaling. The role of other pathways cannot
be ruled out.
Similar to navitoclax, we found that MCL-1 is a resist-
ance factor for the BCL-XL-selective inhibitor A-
1155463. Mechanistically, A-1155463 and navitoclax dis-
place pro-apoptotic protein BIM from BCL-XL, which
leads to the activation of apoptosis [2, 25]. In resistant
cells, it is likely that the BIM released by BCL-XL inhibi-
tor is readily sequestered by MCL-1, thereby inhibiting
the activation of the apoptotic pathway. Indeed, it has
been shown that MCL-1 and BCL-XL play compensatory
roles in regulating apoptosis in most solid tumor cell
lines [13, 16, 26]. Our experiments further demonstrate
that silencing MCL-1 can sensitize solid tumor cell lines
to selective BCL-XL inhibition, expanding on earlier
studies with the BCL-2/BCL-XL inhibitors ABT-737 and
ABT-263 [27–30]. By targeting MCL-1 via mTOR inhib-
ition, colorectal cancers with Kras or BRAF mutations
are sensitized to BCL-2/BCL-XL inhibition [31]. Our ob-
servation that silencing NOXA could rescue sensitive
cells from A-1155463 also supports the role of MCL-1
as a resistance factor. NOXA is known to interact with
MCL-1 and neutralize its activity by targeting this pro-
tein for degradation [1]. Thus, silencing NOXA de-
creases the antagonism of MCL-1, leaving it free to
sequester pro-apoptotic proteins and prevent the activa-
tion of apoptosis [13].
Other gene amplifications have served as therapeutic
targets for other cancers. For example, the MET and
ALK tyrosine kinase inhibitor crizotinib (PF-02341066)
shows differential antitumor effects in non-small cell
lung and gastric cancer according to MET and ALK al-
terations [32]. By utilizing genomic data to identify tu-
mors with BCL2L1 gain, we identified colorectal cancers
as being potentially more dependent on BCL-XL and
more susceptible to BCL-XL inhibition. Indeed, by using
a potent and selective BCL-XL inhibitor, A-1155643, we
have shown that BCL-XL inhibition is sufficient to kill
colon cancer cell lines expressing high levels of BCL-XL
and the MCL-1-neutralizing protein NOXA. Of particu-
lar interest, sensitive lines are enriched in a gain ofBCL2L1, suggesting BCL2L1 gain could be used as a pa-
tient stratification biomarker. This finding demonstrates
the power of identifying potential new targets by exam-
ining genomic regions that undergo frequent alterations
as well as the utility of highly potent and selective tool
molecules. Finally, BCL-XL selective inhibitors may have
utility as therapeutics for the treatment of colorectal
cancer, a disease for which there is significant unmet
medical need.
Conclusions
BCL-XL inhibition could be an effective treatment for
colorectal tumors with high BCL-XL and NOXA expres-
sion. Additionally, BCL2L1 gain may represent stratifica-
tion biomarker for colorectal cancer patients undergoing
treatment with a BCL-XL inhibitor. Future studies should
investigate the utility of BCL2L1 gain as a stratification
biomarker.
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